Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.

Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Järvinen H, Diamant M

Diabetes care1 Sept 2011Cited by 204 (Europe PMC)

PMID21868779PMCIDPMC3161303DOI10.2337/dc11-0291PepBankPUB-21868779

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide and insulin glargine produced similar glycemic control after 3 years.
In plain wordsIn patients with diabetes taking metformin, exenatide and insulin glargine produced similar glucose control.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGlycemic control
Study
n = 36
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Measurements
Glycemic control
6.6%
exenatide
Glycemic control
6.9%
insulin glargine
Source sentences
Summary
At 3 years, EXE and GLAR resulted in similar levels of glycemic control: 6.6 ± 0.2% and 6.9 ± 0.2%, respectively (P = 0.186).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomized to EXE or GLAR.
Summary · context
Thirty-six completed (EXE: n = 16; GLAR: n = 20) the 3-year exposure period.
Report a problemFND-2186877901
02HumanRandomized controlled trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide reduced body weight more than insulin glargine.
In plain wordsIn patients with diabetes taking metformin, exenatide reduced weight more than insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 36
Comparator
Insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Measurements
Body weight difference
−7.9 kg
exenatide versus insulin glargine
Source sentences
Summary
EXE compared with GLAR significantly reduced body weight (-7.9 ± 1.8 kg; P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomized to EXE or GLAR.
Summary · context
Thirty-six completed (EXE: n = 16; GLAR: n = 20) the 3-year exposure period.
Report a problemFND-2186877902
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, disposition index increased after exenatide but decreased after insulin glargine following the off-drug period.
In plain wordsIn patients with diabetes, the disposition index increased after exenatide but decreased after insulin glargine following treatment withdrawal.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseDisposition index
Study
n = 36
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Measurements
Disposition index change
1.43 not stated
exenatide
Disposition index change
−0.99 not stated
insulin glargine
Source sentences
Summary
Following the 4-week off-drug period, the DI, compared with pretreatment, increased with EXE, but decreased with GLAR (1.43 ± 0.78 and -0.99 ± 0.65, respectively; P = 0.028).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomized to EXE or GLAR.
Summary · context
Thirty-six completed (EXE: n = 16; GLAR: n = 20) the 3-year exposure period.
Report a problemFND-2186877904
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide increased the M value after the off-drug period.
In plain wordsIn patients with diabetes, insulin sensitivity increased from pretreatment after exenatide and a four-week period without treatment.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInsulin sensitivity M value
Study
n = 16
Comparator
Pretreatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 yearsAs given in this study (human).
Measurements
M value increase
39%
after 4-week off-drug period
Source sentences
Summary
After the 4-week off-drug period, EXE increased the M value by 39% (P = 0.006) while GLAR had no effect (P = 0.647).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomized to EXE or GLAR.
Summary · context
Thirty-six completed (EXE: n = 16; GLAR: n = 20) the 3-year exposure period.
Report a problemFND-2186877903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00097500

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

AstraZenecan = 69Sept 2004 to Dec 2009

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 7 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.